|
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Background:
PTK787/ZK 222584 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. This is a Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable malignant mesothelioma.
Location/Contact Information:
Study chairs or principal investigators
Thierry Jahan, MD, Study Chair
University of California San Francisco
|
 |
|
